Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuation versus interruption of LV5FU2-paclitaxel after 6 weeks in non-progressive metastatic esophageal squamous cell carcinoma
2017-003660-13Phase 2Terminated
- Sponsor
- Centre Oscar Lambret
- Start
- Mar 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, fluorouracil and folinic acid in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Centre Oscar Lambret. Primary endpoints: Overall survival from randomization and Survival after 30 weeks following randomization. Started Mar 2018; status: terminated.
02
Drugs
paclitaxelfluorouracilfolinic acid
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2017-003660-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003660-13.